GLAXOPharmaceuticals
GlaxoSmithKline Pharmaceuticals Ltd — Profit & Loss Statement
₹2283.00
-3.43%
GlaxoSmithKline Pharmaceuticals Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 18.51 Cr | -26.04 Cr | 8.16 Cr | 3.75 Cr | — |
| Tax Rate For Calcs | 0.25 | 0.28 | 0.27 | 0.30 | — |
| Normalized EBITDA | 1.26K Cr | 981.62 Cr | 874.14 Cr | 836.74 Cr | — |
| Total Unusual Items | 72.83 Cr | -93.95 Cr | 29.84 Cr | 12.49 Cr | — |
| Total Unusual Items Excluding Goodwill | 72.83 Cr | -93.95 Cr | 29.84 Cr | 12.49 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 927.58 Cr | 589.96 Cr | 607.64 Cr | 380.77 Cr | — |
| Reconciled Depreciation | 66.79 Cr | 69.68 Cr | 65.77 Cr | 68.19 Cr | — |
| Reconciled Cost Of Revenue | 1.47K Cr | 1.42K Cr | 1.36K Cr | 1.45K Cr | — |
| EBITDA | 1.33K Cr | 887.67 Cr | 903.98 Cr | 849.23 Cr | — |
| EBIT | 1.26K Cr | 817.99 Cr | 838.21 Cr | 781.04 Cr | — |
| Net Interest Income | 70.07 Cr | 66.05 Cr | 68.00 Cr | 69.16 Cr | — |
| Interest Expense | 1.31 Cr | 1.80 Cr | 1.81 Cr | 2.00 Cr | — |
| Interest Income | 71.38 Cr | 67.85 Cr | 69.81 Cr | 71.15 Cr | — |
| Normalized Income | 873.26 Cr | 657.87 Cr | 585.96 Cr | 372.02 Cr | — |
| Net Income From Continuing And Discontinued Operation | 927.58 Cr | 589.96 Cr | 610.69 Cr | 1.69K Cr | — |
| Total Expenses | 2.61K Cr | 2.60K Cr | 2.48K Cr | 2.57K Cr | — |
| Rent Expense Supplemental | 1.98 Cr | 2.01 Cr | 2.10 Cr | 1.81 Cr | — |
| Diluted Average Shares | 16.94 Cr | 16.94 Cr | 16.94 Cr | 16.94 Cr | — |
| Basic Average Shares | 16.94 Cr | 16.94 Cr | 16.94 Cr | 16.94 Cr | — |
| Diluted EPS | 54.76 | 34.83 | 36.05 | 100.04 | — |
| Basic EPS | 54.76 | 34.83 | 36.05 | 100.04 | — |
| Diluted NI Availto Com Stockholders | 927.58 Cr | 589.96 Cr | 610.69 Cr | 1.69K Cr | — |
| Net Income Common Stockholders | 927.58 Cr | 589.96 Cr | 610.69 Cr | 1.69K Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 927.58 Cr | 589.96 Cr | 610.69 Cr | 1.69K Cr | — |
| Net Income Including Noncontrolling Interests | 927.58 Cr | 589.96 Cr | 610.69 Cr | 1.69K Cr | — |
| Net Income Continuous Operations | 927.58 Cr | 589.96 Cr | 607.64 Cr | 380.77 Cr | — |
| Tax Provision | 332.30 Cr | 226.23 Cr | 228.76 Cr | 398.28 Cr | — |
| Pretax Income | 1.26K Cr | 816.19 Cr | 836.40 Cr | 779.05 Cr | — |
| Other Non Operating Income Expenses | 4.90 Cr | 5.08 Cr | 0.04 Cr | 3.70 Cr | — |
| Special Income Charges | 3.18 Cr | -142.73 Cr | -0.94 Cr | 11.90 Cr | — |
| Other Special Charges | -3.18 Cr | -20.58 Cr | -10.43 Cr | -31.72 Cr | — |
| Restructuring And Mergern Acquisition | 0.00 | 163.30 Cr | 11.37 Cr | 20.08 Cr | — |
| Net Non Operating Interest Income Expense | 70.07 Cr | 66.05 Cr | 68.00 Cr | 69.16 Cr | — |
| Interest Expense Non Operating | 1.31 Cr | 1.80 Cr | 1.81 Cr | 2.00 Cr | — |
| Interest Income Non Operating | 71.38 Cr | 67.85 Cr | 69.81 Cr | 71.15 Cr | — |
| Operating Income | 1.11K Cr | 838.49 Cr | 748.43 Cr | 698.83 Cr | — |
| Operating Expense | 1.14K Cr | 1.18K Cr | 1.12K Cr | 1.12K Cr | — |
| Other Operating Expenses | 272.49 Cr | 268.73 Cr | 272.90 Cr | 210.66 Cr | — |
| Depreciation And Amortization In Income Statement | 66.79 Cr | 69.68 Cr | 65.77 Cr | 68.19 Cr | — |
| Amortization | 10.22 Cr | 10.54 Cr | 9.69 Cr | 9.47 Cr | — |
| Depreciation Income Statement | 56.57 Cr | 59.14 Cr | 56.07 Cr | 58.72 Cr | — |
| Selling General And Administration | 239.28 Cr | 228.40 Cr | 207.08 Cr | 237.22 Cr | — |
| Selling And Marketing Expense | 187.60 Cr | 179.77 Cr | 166.26 Cr | 183.10 Cr | — |
| General And Administrative Expense | 51.68 Cr | 48.63 Cr | 40.82 Cr | 54.12 Cr | — |
| Rent And Landing Fees | 1.98 Cr | 2.01 Cr | 2.10 Cr | 1.81 Cr | — |
| Gross Profit | 2.25K Cr | 2.02K Cr | 1.87K Cr | 1.81K Cr | — |
| Cost Of Revenue | 1.47K Cr | 1.42K Cr | 1.36K Cr | 1.45K Cr | — |
| Total Revenue | 3.73K Cr | 3.44K Cr | 3.23K Cr | 3.26K Cr | — |
| Operating Revenue | 3.73K Cr | 3.44K Cr | 3.23K Cr | 3.26K Cr | — |
| Net Income Discontinuous Operations | — | 0.00 | 3.04 Cr | 1.31K Cr | 70.88 Cr |
| Write Off | — | — | 0.00 | 1.44 Cr | 0.00 |
| Impairment Of Capital Assets | — | — | 0.00 | -1.70 Cr | 209.00 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on GlaxoSmithKline Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.